HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Journal:

Journal of Clinical Oncology

Published:

2025-12-11

DOI:

10.1200/jco-25-02600

Affiliations:

26

Authors:

22

Go to article

Institutions	Authors	Share
Pfizer AG, Switzerland	2.000000	0.09
Pfizer, United States of America (USA)	2.000000	0.09
Centre Eugène Marquis (CEM), France	1.000000	0.05
Kyushu Cancer Center, Japan	1.000000	0.05
Sunnybrook Health Sciences Centre, U of T, Canada	1.000000	0.05
Yonsei Cancer Hospital, South Korea	1.000000	0.05
The Ottawa Hospital (TOH), Canada	1.000000	0.05
Showa Medical University Hospital, Japan	1.000000	0.05
Institut de Recherche en Cancérologie de Montpellier (IRCM), France	1.000000	0.05
Curie Institute, France	1.000000	0.05
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	1.000000	0.05
Liga Norte Riograndense Contra o Câncer, Brazil	1.000000	0.05
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.05
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.05
Sarah Cannon Research Institute (SCRI), United States of America (USA)	1.000000	0.05
Mayo Clinic, United States of America (USA)	1.000000	0.05
Centro Regional Integrado de Oncologia (CRIO), Brazil	1.000000	0.05
IRCCS European Institute of Oncology (IEO), Italy	0.500000	0.02
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.02
University of Milan (UNIMI), Italy	0.500000	0.02
Spanish Research Group on Breast Cancer (GEICAM), Spain	0.333333	0.02
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.333333	0.02
Gregorio Marañon University Hospital, Spain	0.333333	0.02

Interested in Oncology and Carcinogenesis?